Recent

% | $
Quotes you view appear here for quick access.

Array BioPharma Inc. Message Board

  • siriusjaz siriusjaz Jul 22, 2013 4:13 PM Flag

    July 22, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report top-line results

    BOULDER, Colo., July 22, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report top-line results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist and hold a conference call to discuss those results on Tuesday, July 23, 2013. Ron Squarer, Chief Executive Officer, will lead the call.

 
ARRY
3.175-0.035(-1.09%)12:33 PMEDT